These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 30815751)
21. Phase II drugs under investigation for allergic conjunctivitis. Baiula M; Spampinato S Expert Opin Investig Drugs; 2014 Dec; 23(12):1671-86. PubMed ID: 25062902 [TBL] [Abstract][Full Text] [Related]
22. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Yanni JM; Sharif NA; Gamache DA; Miller ST; Weimer LK; Spellman JM Acta Ophthalmol Scand Suppl; 1999; (228):33-7. PubMed ID: 10337430 [TBL] [Abstract][Full Text] [Related]
23. [Pollinosis: drug treatments]. Harf R Rev Mal Respir; 2013 Jun; 30(6):458-62. PubMed ID: 23835318 [TBL] [Abstract][Full Text] [Related]
24. What is the most effective topical treatment for allergic conjunctivitis? Schulz S; Adam P J Fam Pract; 2015 May; 64(5):315, 21. PubMed ID: 26009742 [No Abstract] [Full Text] [Related]
25. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids. Blaiss MS Curr Med Res Opin; 2008 Mar; 24(3):821-36. PubMed ID: 18257976 [TBL] [Abstract][Full Text] [Related]
26. Allergic conjunctivitis: an update on diagnosis and management. O'Brien TP Curr Opin Allergy Clin Immunol; 2013 Oct; 13(5):543-9. PubMed ID: 23974684 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Mah FS; O'Brien T; Kim T; Torkildsen G Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176 [TBL] [Abstract][Full Text] [Related]
34. Seasonal and perennial allergic conjunctivitis. Wong AH; Barg SS; Leung AK Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):118-27. PubMed ID: 19519588 [TBL] [Abstract][Full Text] [Related]
35. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Greiner JV; Udell IJ Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305 [TBL] [Abstract][Full Text] [Related]
37. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Avunduk AM; Tekelioglu Y; Turk A; Akyol N Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412 [TBL] [Abstract][Full Text] [Related]
38. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Abelson MB; Lanier RQ Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434 [TBL] [Abstract][Full Text] [Related]
39. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G; Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286 [TBL] [Abstract][Full Text] [Related]
40. Hyposensitization in the treatment of resistant cases of vernal keratoconjunctivitis. Mahdy RA; Nada WM; Shahien EA; Boghdadi GA; Marei AA Cutan Ocul Toxicol; 2010 Sep; 29(3):198-202. PubMed ID: 20670088 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]